Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection

被引:31
作者
Buijs, P. R. A. [1 ]
van Eijck, C. H. J. [1 ]
Hofland, L. J. [2 ]
Fouchier, R. A. M. [3 ]
van den Hoogen, B. G. [3 ]
机构
[1] Erasmus MC, Dept Surg, NL-3015 CE Rotterdam, Netherlands
[2] Erasmus MC, Dept Internal Med, Div Endocrinol, NL-3015 CE Rotterdam, Netherlands
[3] Erasmus MC, Dept Virosci, NL-3015 CE Rotterdam, Netherlands
关键词
pancreatic adenocarcinoma; oncolytic virotherapy; Newcastle disease virus; innate immunity; I INTERFERONS; CANCER-CELLS; TUMOR-CELLS; THERAPY; NDV; REPLICATION; TRIAL; CHEMOTHERAPY; GEMCITABINE; VIROTHERAPY;
D O I
10.1038/cgt.2013.78
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Newcastle disease virus (NDV) is a naturally occurring oncolytic virus with clinically proven efficacy against several human tumor types. Selective replication in and killing of tumor cells by NDV is thought to occur because of differences in innate immune responses between normal and tumor cells. In our effort to develop oncolytic virotherapy with NDV for patients with pancreatic cancer, we evaluated the responses to NDV infection and interferon (IFN) treatment of 11 different established human pancreatic adenocarcinoma cell lines (HPACs). Here we show that all HPACs were susceptible to NDV. However, this NDV infection resulted in different replication kinetics and cytotoxic effects. Better replication resulted in more cytotoxicity. No correlation was observed between defects in the IFN pathways and, NDV replication or NDV-induced cytotoxicity. IFN production by HPACS after NDV infection differed substantially. Pretreatment of HPACs with IFN resulted in diminished NDV replication and decreased the cytotoxic effects in most HPACs. These findings Suggest that not all HPACs have functional defects in the innate immune pathways, possibly resulting in resistance to oncolytic virus treatment. These data support the rationale for designing recombinant oncolytic NDVs with optimized virulence that should likely contain an antagonist of the IFN pathways.
引用
收藏
页码:24 / 30
页数:7
相关论文
共 45 条
[21]   Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method [J].
Livak, KJ ;
Schmittgen, TD .
METHODS, 2001, 25 (04) :402-408
[22]   Oncolytic Specificity of Newcastle Disease Virus Is Mediated by Selectivity for Apoptosis-Resistant Cells [J].
Mansour, Mena ;
Palese, Peter ;
Zamarin, Dmitriy .
JOURNAL OF VIROLOGY, 2011, 85 (12) :6015-6023
[23]   Short tandem repeat profiling provides an international reference standard for human cell lines [J].
Masters, JR ;
Thomson, JA ;
Daly-Burns, B ;
Reid, YA ;
Dirks, WG ;
Packer, P ;
Toji, LH ;
Ohno, T ;
Tanabe, H ;
Arlett, CF ;
Kelland, LR ;
Harrison, M ;
Virmani, A ;
Ward, TH ;
Ayres, KL ;
Debenham, PG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (14) :8012-8017
[24]   CHARACTERIZATION OF TRYPSINOGEN-1 AND TRYPSINOGEN-2 IN 2 HUMAN PANCREATIC ADENOCARCINOMA CELL-LINES - CFPAC-1 AND CAPAN-1 [J].
MISZCZUKJAMSKA, B ;
MERTEN, M ;
GUYCROTTE, O ;
AMOURIC, M ;
CLEMENTE, F ;
SCHOUMACHER, RA ;
FIGARELLA, C .
FEBS LETTERS, 1991, 294 (03) :175-178
[25]   Type I interferons as radiosensitisers for pancreatic cancer [J].
Morak, Marjolein J. M. ;
van Koetsveld, Peter M. ;
Kanaar, Roland ;
Hofland, Leo J. ;
van Eijck, Casper H. J. .
EUROPEAN JOURNAL OF CANCER, 2011, 47 (13) :1938-1945
[26]   Vesicular Stomatitis Virus as an Oncolytic Agent against Pancreatic Ductal Adenocarcinoma [J].
Murphy, Andrea M. ;
Besmer, Dahlia M. ;
Moerdyk-Schauwecker, Megan ;
Moestl, Natascha ;
Ornelles, David A. ;
Mukherjee, Pinku ;
Grdzelishvili, Valery Z. .
JOURNAL OF VIROLOGY, 2012, 86 (06) :3073-3087
[27]   Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection A Randomized Controlled Trial [J].
Neoptolemos, John P. ;
Stocken, Deborah D. ;
Bassi, Claudio ;
Ghaneh, Paula ;
Cunningham, David ;
Goldstein, David ;
Padbury, Robert ;
Moore, Malcolm J. ;
Gallinger, Steven ;
Mariette, Christophe ;
Wente, Moritz N. ;
Izbicki, Jakob R. ;
Friess, Helmut ;
Lerch, Markus M. ;
Dervenis, Christos ;
Olah, Attila ;
Butturini, Giovanni ;
Doi, Ryuichiro ;
Lind, Pehr A. ;
Smith, David ;
Valle, Juan W. ;
Palmer, Daniel H. ;
Buckels, John A. ;
Thompson, Joyce ;
McKay, Colin J. ;
Rawcliffe, Charlotte L. ;
Buechler, Markus W. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (10) :1073-1081
[28]   PANCREATIC TRYPSINOGEN AND CATHEPSIN-B IN HUMAN PANCREATIC CARCINOMAS AND ASSOCIATED METASTATIC LESIONS [J].
OHTA, T ;
TERADA, T ;
NAGAKAWA, T ;
TAJIMA, H ;
ITOH, H ;
FONSECA, L ;
MIYAZAKI, I .
BRITISH JOURNAL OF CANCER, 1994, 69 (01) :152-156
[29]   Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers [J].
Pecora, AL ;
Rizvi, N ;
Cohen, GI ;
Meropol, NJ ;
Sterman, D ;
Marshall, JL ;
Goldberg, S ;
Gross, P ;
O'Neil, JD ;
Groene, WS ;
Roberts, MS ;
Rabin, H ;
Bamat, MK ;
Lorence, RM .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (09) :2251-2266
[30]   Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus [J].
Puhlmann, J. ;
Puehler, F. ;
Mumberg, D. ;
Boukamp, P. ;
Beier, R. .
ONCOGENE, 2010, 29 (15) :2205-2216